






Type 2 Diabetes (T2DM) prevalence is increasing globally, particularly in resource-limited 
settings where infectious diseases are also highly prevalent. Little is known about prevalence of 
T2DM and prediabetes among HIV positive (HIV+) individuals in Africa. The aim of this study 
was to estimate T2DM and prediabetes prevalence and to describe T2DM and prediabetes risk 
factors among HIV+ patients receiving care at Parirenyatwa Hospital Family Care Center in 
Zimbabwe (PHFCC). Adult HIV+ patients attending visits for routine CD4 count testing 
between July-August 2015 were enrolled (n=244). Nearly all the participants (95.5%) were on 
anti-retroviral therapy (ART) with 18.4% having been on a protease inhibitor (PI)-based 
regimen. T2DM was defined by hemoglobin A1c (HbA1c) ≥ 6.5% or prior clinical records 
indicating T2D diagnosis while prediabetes was defined by HbA1c from 5.7 - 6.4%. Information 
on sex, age, BMI, reported history of family diabetes, ART medication history, CD4 count and 
full blood count reports was collected. Among the 244 HIV+ participants, 17 (7.0%) had T2DM 
and 111 (45.4%) had prediabetes. In models fully adjusted for age, BMI, anemia and protease 
inhibitor (PI) use, BMI was positively associated with prediabetes (OR 1.07, 95% CI 1.02- 1.12) 
and T2DM (OR 1.14, 95% CI 1.04-1.24). Age (OR 1.12, 95% CI 1.06-1.19) was only associated 
with T2DM but not prediabetes.  The age adjusted prevalence of diabetes and prediabetes were 
4.1% and 45.3% respectively while age the standardized prevalence were 10.2% and 42.6% 
respectively. These data indicate that HIV+ patients in Africa are experiencing a notable burden 
of T2DM. A better understanding of the influences associated with the risk for T2DM and its 
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 Introduction and Study Aims 
 
Introduction  
Type 2 Diabetes Mellitus (T2DM) previously belonged to a cohort of diseases that were deemed 
“diseases of affluence” or “western diseases.” The two phrases indicated both location and 
lifestyle and suggested that diabetes was not be found in areas outside the “West” or among the 
poor. While this might have been a convenient truth of the past, it no longer fits with today’s 
understanding of diabetes. Forces imposed by rapid urbanization/westernization, nutrition 
transition, increasing sedentary lifestyles and rising obesity levels have driven diabetes to 
become a global epidemic that is spread out across country boarders and across socio-economic 
strata.1-2 Diabetes is now the reality of both the poor and rich regardless of where they live.  
 
Diabetes is a metabolic disease caused by deficiencies in insulin production and/or function. 
Insulin is central to diabetes primarily because of its role in the metabolism of glucose as it 
regulates the recruitment of Glut 4 transporters under conditions of increased blood glucose as 
well as other metabolic enzymes that function in anabolic pathways for glucose and storage 
mechanisms for glycogen.3-4  According to the American Diabetes Association, diabetes (or 
diabetes mellitus) is a condition characterized by hyperglycemia resulting from the body’s 
inability to use blood glucose for energy.5 There are two main types of diabetes. Type 1 diabetes 
(T1D), which comprises of 5 to 10% of all diabetes  cases, is considered to be an autoimmune 





2 Diabetes Mellitus (T2DM), which comprises approximately 90% of diabetes cases, is a 
metabolic syndrome associated with both reduced insulin production and impaired insulin 
signaling.8-9 Prediabetes  is a term that refers to a transition state in which the amount of glucose 
in the blood is above the normal ranges but not high enough to be considered as diabetes.10 
According to recent CDC reports, 15 to 30% of people with prediabetes will develop diabetes 
within 5 years unless they make appropriate lifestyle changes.11 The focus of this investigation is 
on T2DM and prediabetes. 
 
Global estimates of diabetes prevalence suggest that 350 million people are currently living with 
the disease. 12 Developing countries, especially in Africa, are projected to bear the brunt of the 
increasing incidence of T2DM. Estimates suggest that in the next 20 years, the largest of 
proportional increases in T2DM prevalence are expected to be in Africa with some projections 
suggesting increases of a 109%.12-13 Currently, the prevalence of diabetes varies on the continent 
with national prevalence ranging from 1% in rural Uganda to 12% in urban Kenya.14 
Furthermore, estimates from the IDF indicate that 75% of diabetes cases in sub-Saharan African 
(SSA) remain undiagnosed.15  
 
The increasing diabetes prevalence in Africa has also been caused by a consortium of factors. 
Global factors like technological developments, shifts in income per capita and expansion of 
global trade have been key drivers in steering the world’s dietary and activity/inactivity 
patterns.16-17 In many low and middle income countries, changes in diet, urbanization and 
reduced physical activity have similarly contributed to the rise of the diabetes.16 Several studies 





the combined effects of ageing and nutrition transition, the WHO predicts an increase of 15% in 
non-communicable disease deaths.18 The amalgamation of these risk factors presents a unique 
challenge for those in SSA that live with HIV infection. Given the increased access to ART, HIV 
mortality has decreased and HIV infected people live longer lives that are at increasing risk for 
developing non-communicable diseases like diabetes. 
 
Additionally, there has been also been growing interest in investigating diabetes PLHIV because 
antiretroviral therapy (ART) use has been associated with diabetes. One study, for instance, 
found that ART experienced PLHIV had 4 times the incident rate of diabetes compared to those 
HIV negative participants.20 In a review article on diabetes and HIV, Murphy and Gerard report 
that PLHIV following treatment with some first generation ART drug classes (protease 
inhibitors) had higher rates of diabetes incidence compared to HIV negative participants.21  
Nigatu et all also conducted a systematic review and their results found that cumulative exposure 
to cART (combination Antiretroviral treatment) was linked to increases in the incidence of 
diabetes and that the use of Stavudine and Zidovudine (thymidine analogs) was positively 
associated with diabetes onset.22 
 
One country influenced by diabetes and HIV co-occurrence is Zimbabwe. The country is located 
in SSA and finds itself among a small enclave of countries that face a prominent burden of both 
diabetes and HIV. In 2014, 605,100 cases of diabetes were recorded in the country and these 
contributed to the national adult prevalence of 8.83 %.23 An estimated 1.4 million (15%) 





patients on ART were taking Stavudine, a drug that has been implicated in a host of metabolic 
complications, including diabetes.25  
 
Despite this double burden, there is a dearth of literature surrounding diabetes and HIV research 
in Zimbabwe. Given the evidence concerning HIV’s role (via ART mediated pathways) as a 
potential risk factor for diabetes, there is a need for this research to be carried out in Zimbabwe. 
Of particular note is the need to investigate both the prevalence of prediabetes and diabetes 
among HIV + patients as well as any significant risk factors e.g age and ART that may 



















Study Objectives and Aims 
Primary Objective:  
1. To estimate the prevalence of diabetes and prediabetes among PLHIV in Zimbabwe to 
available national data for Zimbabwe. 
 
Secondary Objectives: 
1. To estimate the prevalence of diabetes and prediabetes by gender and age among 
individuals who are HIV +. 
2. To compare diabetes-related risk factors among PLHIV in Zimbabwe by diabetes status. 





















 Literature Review 
 
The Double Burden of Disease 
 
Low- and middle-income countries (LMICs) face a unique double burden of disease from both 
non-communicable diseases and infectious diseases.26-27 Infectious diseases like HIV, account 
for 69% of deaths in Africa.28-29 Much research from the WHO highlights the increasing toll on 
mortality that non-communicable diseases are taking.30 Some of the key drivers for the 
increasing presence of  non-communicable diseases include rapid urbanization, westernization of 
lifestyles, changing dietary lifestyles, increased longevity among other phenomena.31 With these 
changes, there is no longer a dichotomy between chronic disease and infectious disease as 
complex interactions between non-communicable diseases and (chronic) infectious diseases are 
being observed.32-33 LMICs exhibit significant burdens imposed by chronic diseases like 
diabetes, cardiovascular diseases and cancer while simultaneously facing the weighty burdens of 
infectious diseases like TB and HIV/AIDS.33 Synergistic interactions between some non-
communicable diseases and infectious diseases have worsened the impact of the double burden.  
Conditions like diabetes, for instance, have been shown to increase the risk for TB ,and diabetes 
among people with TB has been associated with worse outcomes.34-38  HIV treatment (ART) has 
also been associated with greater risk for development of diabetes and other metabolic 
complications.39-42 With such a double burden of disease, it is increasingly important to 






HIV Pathophysiology  
Human Immunodeficiency Virus (HIV) is a virus that causes Acquired Immunodeficiency 
Syndrome (AIDS).  The virus spreads through the exchange of certain bodily fluids like blood, 
semen, pre-seminal fluid, rectal fluids, vaginal fluids and breast milk.43 HIV is associated with 
mild symptoms including fever, fatigue, diarrhea, weight loss, thrush and/or shingles.44 Left 
untreated, HIV progresses to AIDS usually within a duration of 10 years although this varies 
from individual to individual.44-45 Some people are long-term nonprogressors and remain 
asymptomatic for a prolonged period of time.45 More rare, are elite controllers that are naturally 
able to suppress the virus to levels that are below detectable.45 
 
HIV can be diagnosed using multiple methods. Conventional laboratory tests use immunoassays 
for detection. Many of these assays test for synthetic peptides and recombinant protein antigens 
to detect Immunoglobulin G (IgG), Immunoglobulin M (IgM) and antigens such as p24. IgG, 
IgM and p24 are some of the markers for seroconversion under HIV infection.46 The primary 
principle of testing for antibodies and antigens is included in assays like the Enzyme-Linked 
Immunosorbent Assays (ELISAs), the Western Blot and in Fourth Generation Assays which are 
used within lab-based environments to detect HIV.  46-47 
 
HIV/AIDS cannot be cured but it can be treated by antiretroviral therapy.48 The table below 
summarizes the different drug classes, their method of function and different examples of drugs 







Table 2.1 Summary of Antiretroviral Drug Classes 
Antiretroviral Drug 
Class 
Function Examples of Drugs 
Entry Inhibitors Interfere with the virus’s ability to 
bind to receptors on the outer surface 
of the cell preventing cell infection 
Enfuvirtide 
Fusion inhibitors Interfere with the virus’ ability to 
fuse with a cellular membrane 
preventing HIV entry into the cell 
Enfuvirtide 
Reverse Transcriptase 
Inhibitors (2 Types) 
Nucleoside/Nucleotide Reverse 





Didanosine, Stavudine (d4T), 
Lamivudine, Abacavir, 
Emtricitabine 
Tenofovir (nucleotide RTI) 
Non-Nucleoside Reverse 
Transcriptase Inhibitors interfere 
with ability of HIV to convert HIV 
RNA into DNA which is especially 
important as HIV is a retrovirus 
Nevirapine, Efavirenz, 
Delavirdine 
Integrase inhibitors Block integrase (an HIV enzyme) 
from adding its genetic material into 
the DNA of the host 
Raltegravir 
Protease Inhibitors Interfere with protease (an HIV 
enzyme) preventing the assembly of 






(subset of entry 
inhibitors) 
Prevent HIV infection of CD4-T 




Epidemiology of HIV and ART 
 
HIV/AIDS is perhaps one of the most significant global public health concerns that has faced the 
world in the last half decade. Since 2000, around 38.1 million individuals have become infected 
with HIV and 25.3 million people have died of AIDS-related illnesses.51 The largest burden of 
HIV has grossly been in SSA with an approximate prevalence of 25.8 million and 9 countries 





increased considerably with more people procuring access to ART. Estimates from 2014 
presented by UNAIDS suggest that 41% of all adults living with HIV were accessing 
antiretroviral therapy (ART) which was an improvement from 23% in 2010.51 Between 2004 and 
2014, the number of AIDS related mortality decreased from 2 million to 1.2 million deaths per 
year.51 According to the UNAIDS report, the number of pills, the time it takes for HIV diagnosis 
to be determined, cost of ART have all come down and life expectancy of PLHIV has increased 
from 36 to 55 between 2001 and 2014.51 
 
Incidence has remained stable over the past decade and might be an “after the fact” effect of the 
global incidence peaking around 1997 and decreasing thereafter.53 The increasing emphasis on 
prevention strategies, usage of condoms, increased access to ART among other initiatives have 
greatly decreasing the spread of HIV. Condom campaigns have greatly benefitted several 
countries in SSA like Uganda. 54  The country was able to effect a decline of  70% in HIV 
prevalence which was linked to a 60% reduction in casual sex.54  One important strategy that has 
also contributed to reduced incidence has been screening of blood received into blood banks and 
other transfusion services.55 Some scholars have also commented that the reduction in incidence 
rate is partially due to the fact several of the potential spreaders have also passed away in recent 
past decades.56  
 
HIV transmission in Africa is primarily through unprotected heterosexual transmission although 
mother to child was also prominent. The main mode of transmission in SSA is unprotected 
heterosexual intercourse.57 A metastudy conducted on serodiscordant married couples in Africa 





because it displaces the commonly held notion that men and their sexual behaviors are 
responsible for spreading the virus. This study shows that both men and women equally 
participate in unprotected sex and transmit the virus. This is especially pertinent when trying to 
identify at risk populations. 59 Two key populations, however, that are at higher risk include 
Female Sex Workers (FSW) and people who report paying for sex.57 Another mode of 
transmission that was previously prominent was mother to child transmission although anti-
retroviral therapy has drastically reduced transmission proving to be so effective that it reduces 
vertical transmission to less than 5% in babies up to 24 months.60-61 Although in many western 
countries populations of men who have sex with men (MSM) tend to be the most at risk for 
contracting HIV, in Sub-Saharan Africa it is difficult to ascertain because of the criminalization 
and stigmatization of homosexuality.  
 
Zimbabwe has taken several measures to reduce HIV prevalence as evidenced by the decline 
from 29% to 16% between 1997 and 2007.62 Several factors explain why the prevalence of 
HIV/AIDS has decreased. Condom use among women continues to increase and plays a seminal 
role in the reduction of infection.62 The economic decline in the country also played a role in 
reducing behavior associated with high risk of HIV infection as many men no longer had as 
much disposable income to purchase sex or maintain multiple sexual partners.63 National 
HIV/AIDS campaigns were launched and these targeted changing people’s beliefs about 
HIV/AIDS and augmented knowledge on the diseases. The campaigns were reinforced by 
community action in schools, workplaces, churches and other social environments.62 These 
initiatives were housed in adaptive national policies that constituted an array of policy changes 





risk sexual behavior illustrated by a reduction in the number of people that reported having one 
or more non-regular sexual partners.64 Other pertinent interventions that have contributed to 
reduced prevalence include the Prevention of Mother to Child Transmission (PMTCT), the male 
circumcision program and the voluntary counselling program.65-66 A separate key driver for 
reduced prevalence was the significant number of deaths of people with HIV between 2000 and 
2005.67 While this was not an intervention, it reduced the number of people that were living with 
HIV/AIDS during this time. 
 
 
A central achievement in reduction of HIV mortality has been the ART program. In spite of the 
major accomplishment of this program in Zimbabwe, the country continues to be among WHO’s 
top 20 country with the highest unmet need for ART.68 Estimates from UNAIDS indicates that 
Zimbabwe has an ART coverage of 77% for adults and 46% for children. The WHO estimates 
national  coverage to be 48% which is comparatively higher than other countries like South 
Africa, Mozambique and the DRC but sufficiently worrisome in the case where ART therapy is 
now seen as a means of prevention.69-72  Another advantage of the national ART program is 
reduced mortality and increased life expectancy of PLHIV. Several studies have shown the 
connection between increased life expectancy among people living with HIV and ART.73-75 It is 
this increased longevity and ART intake that has paradoxically brought increased risks for 
chronic diseases. 
 
Type 2 Diabetes Mellitus Pathophysiology 
T2DM is a metabolic syndrome that is caused by impairments that reduce insulin productions 





glucose as glycemia status is balanced by the interplay between insulin action and insulin 
secretion.77 Under normal conditions, insulin release triggers the translocation of glut-4 
transporters to the cell surface membranes of somatic cells.78 The glut 4 transporters then 
subsequently increase the rate at which glucose is absorbed into cells, reducing blood 
concentration of glucose while allowing body cells to access and harness the vital energy in 
glucose. In addition to this, insulin through its signaling pathway hosts a cascade of mechanisms 
that increase synthesis of glycogen, protein, mRNA and other substrates that are essential for cell 
growth and proliferation. 77  
 
In the progression of T2DM, beta cell function is greatly reduced and this is probably due to 
reduced beta cell mass.79 Some studies have estimated that up to 63% of beta cell mass can be 
lost prior to the onset of symptoms.79 Glucose toxicity caused by hyperglycemia has been 
associated with increased reactive oxygen species in the pancreas.77 These increased ROs are 
thought to damage cellular components of the insulin-producing machinery.77 Damage or loss of 
pancreas duodenum homeobox-1 by ROs has been proposed as a vital mechanism for beta cell 
dysfunction that leads to the reduction of insulin production.86 Ordinarily, insulin release occurs 
through 2 phases. In the first phase, insulin is secreted from a readily releasable pool and in the 
second phase, insulin is released from a reserve pool that serves prolonged cellular exposure to 
glucose.81 In T2DM, however, it has been found that there is a loss of the first phase and insulin 
secretion is through the second-phase.81 
 
In addition to glucotoxicity, lipotoxicity has also been recognized as a factor in onset of Type 2 





store fat and once their capacity has been exceeded, there is an overflow of lipid storage that 
occurs in other places like the liver and possibly the beta cells.82 It is this “overflow” that is 
thought to be associated with insulin-resistance, hyperinsulinaemia and dyslipidemia. It is 
thought that lipolytic activity of visceral cells causes increased delivery of free fatty acids to the 
liver and results in increased hepatic insulin resistance.82 Moreover metabolites of triglycerides 
in the liver and muscle e.g ceramides and diacylglycerides are known to impair insulin action in 
these tissues by interfering with insulin signaling and glycogen synthesis while simultaneously 
increasing hepatic gluconeogenesis.76,82 Lipotoxicity is thus a factor in the pathogenesis of Type 
2 Diabetes because of its roles in reducing insulin sensitivity and increasing systemic blood 
glucose (through hepatic gluconeogenesis). 
 
T2DM’s hallmark is hyperglycemia and blood glucose levels and levels of glycemia are used in 
diagnosis. There are various diagnostic criteria that are used to detect different levels of 
glycemia, such as diabetes and prediabetes. The American Diabetes Associations definitions for 
these two conditions are outlined in Table 2.2 . Standard assessments used for diagnosing 
diabetes include using fasting plasma glucose (FPG), 75g oral glucose tolerance testing (OGTT), 
and HbA1c.83 
 
Table 2.2 Diagnostic Criteria for Diabetes and Prediabetes from ADA 







Normoglycemia <5.7 <100 <140 
Prediabetes 5.7 to 6.4 100 to 125 140 to 199 






Similar to HIV infection, there is no cure for T2DM but treatment is available. Pharmacological 
therapy through drugs like metformin, GLP-1 agonists, SGLT-2 inhibitors, thalizodinedione 
(TZD) are available for patients and help to control glycemia.84 In addition to this, insulin 
therapy is also an option for people with newly diagnosed T2DM who have marked symptoms. 84 
These therapies are often combined with lifestyle modification such as increasing physical 
activity, and dietary modification that further promote blood sugar control. 84 
 
Epidemiology of Diabetes  
 
Global prevalence of T2DM has been escalating at an unprecedented rate. 30 million people in 
1985 had diabetes, by 1995, this number has increased to 135 million and in 2015, it was 350 
million people.12,85 A few decades ago, T2DM was relatively rare in most developing countries 
and in countries like China it was previously reported to have been less than 1%.9 New evidence 
indicates that this is no longer the case. China, for example was found to have a diabetes 
prevalence of 11.6% and prediabetes prevalence of 50.1%.86 T2DM prevalence is not just 
increasing in “developed” countries, but it has also been increasing in “developing” countries 
with the latter showing increasing incidence and survival of people with diabetes.87 
 
Sub- Saharan Africa (SSA) is no exception to the increasing prevalence of diabetes. Although 
the data on the prevalence of Type 2 DM in Africa are limited, there is evidence to suggest that 
dramatic increases in prevalence are is occurring.88 T2DM prevalence projections for SSA 
indicate that prevalence will increase from 12.1 million in 2010 to 23.9 million by 2030.89 Of all 





to current prevalence rates by 2030 .90  Similar drivers for increasing global prevalence seem to 
be driving the overall increase in diabetes. The spread of diabetes in developing countries in SSA 
is similarly influenced by the effects of nutrition transition, urbanization, western diets, low 
physical activity, epigenetics, increasing adipocity, etc.44  
 
Available estimates show that there is diversity among and within countries in SSA by 
prevalence of T2DM. A review done by Hall et al suggests that T2DM prevalence in 9 countries 
that used WHO’s STEPwise Approach to Chronic Disease Surveillance Management varied 
from 0.6% in rural Uganda to 12% urban Kenya.14 Other countries like Seychelles and Reunion 
have prevalence estimates that go beyond 12% with both having country prevalence estimates of 
17.4% and 18.2% respectively.15 The review by Hall et al. not only reveals difference by country 
but it also shows that there are differences according to urban versus rural.14 According to the 7th 
edition of the IDF, the majority of people with diabetes (58.8%) live in cities and women have a 
diabetes attributable rate that is 1.7 times higher than that of men.91 
 
Estimates for the prevalence of diabetes specific to Zimbabwe show significant variation due to 
limited data. Pre-independence (pre-1980) pooled prevalence estimates indicate prevalence rates 
of 0.44% but post-independence prevalence was 5.7%.92 More recent estimates from the 
International Diabetes Federation (IDF) Diabetes Atlas 6th and 7th edition indicate conflicting 
estimates. The sixth edition maintains that Zimbabwe had the 4th highest of prevalence of 
diabetes on the continent with an estimated national prevalence of 8.83% while the seventh 
edition indicates that Zimbabwe has a prevalence of 2.9%.15,91 It is unlikely that the prevalence 





epidemiological research in a resource limited area. It also speaks to the point made by Gill et all 
that “accurate estimates of DM based on good epidemiological studies are difficult to find 
because the studies are expensive, labor intensive, suffer challenges like mobile populations and 
are poorly enumerated.”93 
 
 
Background on Prediabetes  
Prediabetes is an intermediary state of hyperglycemia which is above the normal, but not 
sufficiently high enough to be considered diabetes.83 It is a state that includes people that have an 
elevated HbA1c, impaired fasting glucose or have an impaired glucose tolerance.94 
It is diagnosed using the criteria listed in Table 2.3.While it is not a distinctive condition with 
symptoms, it is an intermediate state that is associated with higher risks of developing diabetes 
and cardiovascular diseases.95 
 
Table 2.3 Definitions of Sub-diabetes96-97 
 Definition 













 ≥ 7.8 and < 11.1 mmol/l 














110-125 mg/dL 100- 125 
mg/dL 
Prediabetes   5.7-6.4% 
HbA1c 






Epidemiology of Prediabetes 
 
 The prevalence of prediabetes depends on the method used to define/ assess prediabetes. 
According to NHANES data from 1999-2006, the prevalence of prediabetes was 12.6% using 
HbA1c, but was as high as 28.2% using the fasting glucose method.98 In addition, the reported 
prevalence depends on the criteria being used i.e whether it is the ADA guidelines or another 
institution’s (Table 2.3).95 What has been consistent in the literature is that higher levels of 
HbA1c are associated with incident diabetes.  
 
Variation in prediabetes prevalence has been observed on the continent. In one study in Uganda 
among one thousand four hundred and ninety seven 35 to 60 year olds, the prevalence for 
diabetes was 7.4% (95%CI 6.1-8.8) using a fasting plasma glucose (FPG)  as defined by FPG≥ 
6.9 mmol/L.99 The prevalence of prediabetes was 8.6% (95%CI 7.3-10.2) using WHO criteria 
and 20.2% (95%CI 17.5-22.9) with ADA criteria.99 Given that the ADA defines IFG and 
prediabetes using wider plasma and HbA1c intervals, it follows that more people will fit into this 
categories. This lack of consistency is primarily troubling when mathematical models use 
neighboring country information from previous prevalence estimates to extrapolate current 
diabetes prevalence in another country. In the 7th edition of the diabetes Atlas, no specific 
Zimbabwean study was used to assess current prevalence of diabetes and prediabetes, but the 








HbA1C: A Diagnostic Test For Diabetes 
Hemoglobin A1c (HbA1c) is a blood chemistry test that can be used to diagnose diabetes.100 The 
HbA1c assay, though not the gold standard, is advantageous over the other methods because it 
does not require fasting, has greater pre-analytical stability and less day-to-day perturbations due 
to stress among other strengths.101 This assay, however, is sensitive to age, race/ethnicity and is 
also skewed by hemoglobinopathies.101 Conditions that increase rate of turnover for red blood 
cells e.g hemolytic anemia, chronic malaria also skew the results (Figure 2.1).102  
 
Figure 2.1 Factors That Cause HbA1c to Underestimate or Overestimate Glycemia103 
 
 
The use of HbA1c as a diagnostic tool for diabetes among HIV+ patients has also been brought 





T2DM increases the accuracy of the diagnosis and that in clinical practice, it gives a reasonably 
accurate reflection of glycemia.104-105 On the other hand, researchers like Kim et al and Diop et 
al, have found that HbA1c (when used alone) underestimates glycemia in HIV+ patients on ART 
either because of macrocytosis or hemolysis.106-107 A systematic review on the association HIV 
and ART with cardiometabolic traits in Sub-Saharan African found that ART experienced HIV+ 
people had lower HbA1C (standardized mean difference -0.34; 95% CI -0.62 to -0.06) compared 
to ART-naïve HIV+ patients. 108 A study by Eckhardt et all on the utility of HbA1c as a 
screening tool for incident diabetes found that the test had a 40.9% sensitivity and 97.5% 
specificity.109 The authors found that current ART use affected the ability of HbA1c to 
accurately detect diabetes leading to misclassfication.109 Another Fasting glucose- HbA1c 
discordance study by Slama et all found that at fasting glucose of 125 mg/dL, the median HbA1c 
among HIV-infected men was 0.21% lower than among HIV-uninfected men.110  Similar to the 
Eckhardt study mentioned above, discordance was associated with CD4 cell count< 500 cells/m3, 
use of a PI, zidovudine and/or lamivudine  containing regimen and higher MCV and MCH. 110 
ART regimens including PI have also been found to mitigate the effectiveness of diabetes 
therapy that aims to reduce HbA1c among people with diabetes. 110 People on the therapy that 
were on PI based regimens had the least reduction in HbA1c compared to HIV-uninfected 
patients. 110 
 
Other studies that focused on hematological parameters found that low red cell distribution width 
(RDW) was associated with increased HbA1c and incidence of T2DM.112 Changing ART 
medications was also associated with decreased HbA1c and one study found that when patients 





and this was accompanied by reductions in total white blood count and absolute neutrophil 
count.113 This study suggests that ZDV may cause bone marrow suppression which can 
eventually lead to anemia.113  This latter study ties in well with evidence from Attard et al which 
suggests that HbA1c misclassifies diabetes status in people with endemic ID/anemia. 114 Given 
the above findings, it is likely that HbA1c underestimates glycemia among HIV+ patients on 
ART. 
 
Diabetes and HIV 
 
HIV per se does not seem to be a risk factor for diabetes.115 Many studies have found that people 
with HIV do not have drastically different rates/risks of diabetes incidence compared to non-HIV 
infected people after adjusting for variables like age and bmi.115-116 One study found that fasting 
glucose was similar between treatment naïve patients and HIV negative patients.20 Some current 
studies suggest that virological influences like duration of HIV, high viral load, low CD4 count 
can contribute to diabetes onset.117 Additional studies maintain that diabetes onset might be 
caused by HIV-coinfections but there are conflicting results as some have found associations 
with Hepatitis C Virus while other studies found no associations with either Hepatitis B or 
Hepatitis C.118-119 
 
Several diabetes risk factors have, however, been identified from HIV treatment as there have 
been associations between HIV medication and diabetes onset.120 The earliest reported cases of 
treatment-related DM were associated with pentamidine treatment of Pnuemocytosis carini- a 





pancreatic beta cells and was found to induce insulin deficiency and ketoacidosis among other 
complications.121 Since then a host of metabolic complications have been associated with anti-
retroviral therapy.122-124 Later studies have found that there is an increased incidence of diabetes 
with exposure to ART and the strongest associations have been with Stavudine, Zidovudine and 
Didanosine. 125   
 
Highly active ART likely leads to increased risks for metabolic dysfunction including insulin 
resistance, diabetes dyslipidemia and lipodystrophy. 118,126-127 Protease Inhibitors (PIs) are 
thought to increase insulin resistance by interfering with Glut 4 transporter recruitment, lipid 
metabolism and beta cell function .118,120, 128 One review found that 30-40% of patients taking PIs 
had impaired glucose tolerance and further implicates PIs in the progression of type 2 
diabetes.129,21Another class of medications that has also been associated with diabetes are 
nucleoside reverse transcriptase inhibitors (NRTIs) and some have been found to increase the 
risk of diabetes.125 The mechanism is not known but some of the causative routes proposed 
include insulin resistance, lipodystrophy and mitochondrial dysfunction as these effects are 
commonly seen with chronic intake of NRTIs (see figures 2.2 and 2.3 below).130 As a last caveat, 
it is important to note that not all antiretroviral therapy drugs that are in the same class have the 











Figure 2.2 Proposed Mechanism For the Action NRTIs and PIs on Metabolism131 
Pratibha V. et all Sterol regulatory element-binding proteins and reactive oxygen species: potential role in highly-active antiretroviral 















Figure 2.3 Proposed Mechanism For the Action of PIs on Diabetes Onset126 
 
Larson et all. "Disorders of glucose metabolism in the context of human immunodeficiency virus infection." Journal of the American 
Academy of Nurse Practitioners Volume 18, Issue 3, pages 92-103,  
 
Given the evidence presented above on the prominent role of the ART Program in Zimbabwe on 
curbing HIV/AIDS related mortality, the question of HIV and diabetes is all the more relevant. 
The toll that HIV has had in this country has made dealing with the disease a priority for the 
country. In the context of the contemporary era of health systems strengthening, it has never 
been more relevant to assess the effectiveness and efficiency of current health systems.132 The 
issues that Samaras et all raise ring true when it comes to strengthening HIV care and reducing 
HIV/AIDS related commorbities.133 By virtue of its efforts, Zimbabwe seems to be gaining in the 
battle with HIV, but this battle is facilitating a new battle; a battle with chronic infectious 



































Type 2 Diabetes (T2DM) prevalence is increasing globally, particularly in resource-limited 
settings where infectious diseases are also highly prevalent. Little is known about prevalence of 
T2DM and prediabetes among HIV positive (HIV+) individuals in Africa. The aim of this study 
was to estimate T2DM and prediabetes prevalence and to describe T2DM and prediabetes risk 
factors among HIV+ patients receiving care at Parirenyatwa Hospital Family Care Center in 
Zimbabwe (PHFCC). Adult HIV+ patients attending visits for routine CD4 count testing 
between July-August 2015 were enrolled (n=244). Nearly all the participants (95.5%) were on 
anti-retroviral therapy (ART) with 18.4% having been on a protease inhibitor (PI)-based 
regimen. T2DM was defined by hemoglobin A1c (HbA1c) ≥ 6.5% or prior clinical records 
indicating T2D diagnosis while prediabetes was defined by HbA1c from 5.7 - 6.4%. Information 
on sex, age, BMI, reported history of family diabetes, ART medication history, CD4 count and 
full blood count reports was collected. Among the 244 HIV+ participants, 17 (7.0%) had T2DM 
and 111 (45.4%) had prediabetes. In models fully adjusted for age, BMI, anemia and protease 
inhibitor (PI) use, BMI was positively associated with prediabetes (OR 1.07, 95% CI 1.02- 1.12) 
and T2DM (OR 1.14, 95% CI 1.04-1.24). Age (OR 1.12, 95% CI 1.06-1.19) was only associated 
with T2DM but not prediabetes.  The age adjusted prevalence of diabetes and prediabetes were 
4.1% and 45.3% respectively while age the standardized prevalence were 10.2% and 42.6% 
respectively. These data indicate that HIV+ patients in Africa are experiencing a notable burden 
of T2DM. A better understanding of the influences associated with the risk for T2DM and its 










Diabetes is increasingly becoming an important issue to study among people living with HIV 
(PLHIV) in low and middle income countries (LMICs). In these countries, the use of anti-
retroviral therapy has increased longevity of people living with HV (PLHIV) while forces 
imposed by rapid urbanization/westernization, nutrition transition, increasing sedentary lifestyles 
and rising obesity have driven diabetes prevalence.1,2,74,75 Consequently, many low and middle 
income countries now face a “double burden of disease.”26,27 In many of these countries, 
especially in Africa, much of the health infrastructure has been designed to deal with curbing 
HIV mortality but not with the chronic comorbidities.93,134 There is, however, a deficit of 
literature surrounding prevalence of non-communicable diseases like diabetes among PLHIV in 
Africa and the relevant risk factors that may increase their risks of developing diabetes. Current 
evidence suggests that Anti-Retroviral Therapy (ART) may present additional risks for diabetes 
and places HIV positive patients at a higher degree of vulnerability.120 
 
Zimbabwe faces a dual burden of HIV and diabetes that is higher than most countries in Sub-
Saharan Africa (SSA). Diabetes and HIV estimates in Zimbabwe show that prevalence of both 
disease is 8.8%15 and 14.7% 24 respectively which are both significantly higher than those of 
most other countries in SSA. The prevalence of HIV/AIDS is not only worrisome by itself, but 
the widespread use of ART also brings with  it a host of ART-related cardiometabolic effects 
including lipodystrophy, insulin resistance and dyslipidemia.39-42 Historically earlier generations 
of thymidine analogs like Zidovudine and Stavudine were observed to induce diabetes.22 More 





interfering with the recruitment of Glut 4 transporters, lipid metabolism and beta cell 
function.118,120,128 Another class of medications that has also been associated with diabetes are 
nucleoside reverse transcriptase inhibitors (NRTIs) and some have been found to increase the 
risk of diabetes.125 This evidence suggests that some forms of ART may increase risks for 
developing diabetes among ART-experienced people with HIV. 
 
Given the dearth of literature on the topic of diabetes and HIV in Africa, this study principally 
sought to investigate the prevalence of diabetes and prediabetes among HIV positive patients at 
Parirenyatwa Hospital Family Care Center (PHFCC) in Zimbabwe. The study also sought to 
determine pertinent risk factors associated with both conditions among patients including the 
potential association with ART. 
Methods 
This study was a cross-sectional, single visit study in which patients attending routine CD4 count 
testing at Parirenyatwa Hospital Family Care Center (PHFCC) between July and August 2015 
were recruited. Eligible participants were adults (18 years and older) who had documentation 
that proved HIV positive serostatus and were able to provide informed consent. Those that were 
ineligible were pregnant women and patients that had a household/family member already 
recruited by the study. 
 
Recruited patients had their heights and weights measured following a standardized protocol. 
Participants subsequently filled out a health history questionnaire through which they provided 
information on their demographics (age and gender), reported family history of diabetes, 





of diagnosis of HIV, and if applicable, dates of diagnosis of diabetes and records of diabetes 
medication. The hospital Laboratory Information Management System (LIMS) was used to 
collect data on CD4-T cell profiles and complete blood count information. Lastly, a nurse 
phlebotomist collected 1-2 ml aliquots of blood in EDTA vacutainers.  These whole blood 
samples were delivered to Infectious Disease Research Laboratory and processed two to three 
hours after collection. The samples were processed using a Roche COBAS C111 blood 
chemistry analyzer using an NGSP certified HbA1c immunoassay. 
 
BMI was calculated as weight (in kilograms) divided by height (in meters) squared (kg/m2). BMI 
class was categorized as normal weight (<25 kg/m2), overweight (25- 29.9 kg/m2) and obese 
(≥30 kg/m2). HbA1c was classified according to ADA guidelines: normoglycemia (<5.7%), 
prediabetes (5.7 to <6.5 %) and diabetes (≥6.5%). A person was also considered to have diabetes 
if they had a previous diagnosis mentioned in their clinical records or if their clinical records 
showed that they had previously taken diabetes medication (e.g metformin).  
 
The main outcomes for this study was prevalence of diabetes and prediabetes. The prevalence of 
diabetes was estimated using the proportion of people with the above-mentioned criteria for 
diabetes. The prevalence of prediabetes was estimated using the proportion of people with 
prediabetes according to HbA1c. Both of these outcomes were subsequently stratified by gender 
and age. SAS v9.3 statistical package was used to run a multinomial logistic regression model to 
determine association between the outcomes (diabetes/prediabetes/normoglycemia) and the 
following risk factors/confounders: age, BMI, current NNRTI/PI drug use, anemia, alcohol 





the model until a final model (which included age, BMI, anemia status and current NNRTI use) 
was established. In addition to this, SAS v9.3 statistical package was used to run age-adjusted 
prevalence of diabetes and prediabetes using the multinomial logistic model and the distribution 
of age in the sample. Lastly NHANES data from 2011-2012 was used to determine age-
standardized prevalence of both diabetes and prediabetes which was compared to both the US 




This study enrolled 244 people living with HIV (approximately 1.36% of total clinical 
population) and of these 233 (95.5%) were on ART. Of the participants that were on ART, most 
(77.6%) were on an NNRTI based regimen. 17 (7.0%) of participants were found to have 
diabetes and 111 (45.5%) had prediabetes. Of those with diabetes, 9 were classified by HbA1c 
and 10 by previous diagnosis but in two cases, the HbA1c confirmed the previous diagnosis.  
Most participants (94.2%) found to have diabetes were between the ages of 46 and 65 while 91% 
of participants with prediabetes were between the ages of 26 and 65 (Table 3.1).  In addition to 
this, 82.4% of participants with diabetes were either overweight or obese while 49.5% of 















Table 3.1. Distribution of Participant Characteristics by Glycemia Status 







N 244 116 (47.5) 111 (45.5) 17  (7.0)  
Age  (years)~     0.03 
 18-25 17 9   (7.8) 8    (7.2) 0  
 26-45 102 56 (48.7) 44  (39.6) 2 (11.8)  
 46-65 119 48 (41.7) 57  (51.4) 14 (82.4)  
  >65 5 2    (1.7) 2    (1.8) 1 (5.9)  
Gender~     0.07 
 Female 161 73 (62.9) 80 (72.1) 8 (47.1)  
Weight Status¶     0.0004 
Normal weight 131 74 (63.8) 54  (49.5) 3 (17.7)  
 Overweight 63 29 (25.0) 26  (23.9) 8 (47.1)  
 Obesity 48 13 (11.2) 29  (26.6) 6 (35.3)  
Reported History of 
Family Diabetes 
    0.0245 
Yes 62 26 (22.4) 27 (24.3) 9 (52.9)  
No 182 90 (77.6) 84 (75.5) 8 (47.1)  
Smoking     0.1227 
Yes 11 8 (6.9) 2 (1.8) 1 (5.9)  
No 233 108 (93.1) 109 (98.2) 16 (94.1)  
Alcohol consumption     0.3172 
>1 drink per week 14 10 (8.6) 3 (2.7) 1   (5.9)  
1 drink per week 12 5 (4.3) 6 (5.4) 1   (5.9)  
No 218 101 (87.1) 102 (91.9) 15 (88.2)  
ART experienced      0.26 
Currently on PI 
regimen  
41 14 (12.1) 22  (19.8) 5 (29.4)  
 Currently on NNRTI 
regimen 
177 90 (77.6) 77  (69.4) 10 (58.8)  
Not on PI/NNRTI or 
missing 
26 12 (10.3) 12  (10.8) 2  (11.8)  
Anemia Status     0.0473 
Anemia 41 11 (9.5) 27 (24.3) 3   (17.7)  
No anemia 147 76 (65.5)   60 (54.1) 11 (64.7)  
Missing data 56 29 (25.0) 24 (21.6) 3   (17.7)  
CD4 count     0.6479 
Above median 108 48 (41.4) 50 (45.1) 10 (58.8)  
Below median 109 56 (48.3) 48 (43.2) 5 (29.4)  
Missing data 27 12 (10.3) 13 (11.7) 2 (11.8)  
~ 1 missing      ¶ 2 missing   






In the multinomial logistic regression analysis shown in Table 3.2, diabetes was significantly 
associated age (OR 1.12 95 CI% 1.06-1.19) and BMI (OR 1.14 95% CI 1.04-1.24). NNRTI use 
was found to be significantly protective for diabetes (OR 0.244 95 CI% 0.06-0.97) when 
compared to patients taking PI based regimens. Prediabetes (OR 1.07 95% CI 1.02-1.12) was 
also significantly associated with BMI. While there was an association between prediabetes and 
anemia, it is important to note that anemia was not considered as a risk factor for either diabetes 
or prediabetes. Rather, anemia was considered important for sensitivity analysis as it has 
previously been shown to cause misclassification of diabetes status in patients with anemia.114 
 
Table 3.2. Results From Multinomial Logistic Regression 
 Prediabetes Diabetes 
 Odds Ratio 95% CI p-value Odds Ratio 95% CI p-value 
Age (years) 1.00 0.98-1.03 0.7617 1.12 1.06- 1.19 <.0001 
BMI (kg/m2)# 1.07 1.02-1.12 0.0007 1.14 1.04- 1.24 0.0033 
No Anemia 1.00 -  1.00 -  
     Anemia† 3.12 1.38-7.05 0.0061 1.46 0.31-6.92 0.6336 
Missing Anemia 
data† 
1.04 0.54-2.03 0.8987 0.60 0.13-2.70 0.5016 
PI Use 1.00 -  1.00 -  
     NNRTI Use* 0.64 0.30- 1.38 0.2530 0.25 0.06- 0.99 0.0486 
Missing or Not on 
PI/NNRTI* 
0.65 0.21-1.93 0.4371 0.50 0.07-3.59 0.4929 
       
CI, confidence interval; OR, odds ratio. 
*Reference is PI use 
† Anemia has 3 groups: anemia, no anemia and missing. Reference group is no anemia 
 
Other risk factors like reported family history of diabetes, gender, hemoglobin, alcohol, smoking, 
and CD4 count were also added to the model (Table 3.2) but were found to be non-significant 
factors (p-value ≥0.05)  for both diabetes and prediabetes in the fully adjusted model.  In 
additional analysis prediabetes prevalence was stratified by anemia status, PI use, hemoglobin 







In further analysis (Table 3.3), the prevalence of diabetes and prediabetes was age adjusted using 
the distribution of age in the sample. Age adjusted diabetes prevalence was 4.1% while age 
adjusted prevalence of diabetes was 45.3%. The age adjusted prevalence of diabetes was reduced 
because 56.5% of sample was below 46 years and only accounted for 11.8% of the total diabetes 
prevalence (Table 3.1). The age adjusted prevalence of prediabetes was similar because of the 
normal distribution of prediabetes by age (Table 3.1) in the sample.  
 
Table 3.3. Age adjusted and age standardized prevalence of diabetes and prediabetes 
  Prediabetes (%) Diabetes (%) 
Prevalence in this study   
Crude 45.5 7.0 
Age-adjusted* 45.3 4.1 
Age standardized* by NHANES 2011-2012 Data 42.6 10.2 
US Prevalence 2011-2012   
General population 36.5 12.3 
Non-Hispanic black 38.8 20.6 
*Age categories for adjustment or standardization: 18-44, 45-64, >=65 
The prevalence of diabetes and prediabetes was further age standardized according to the US age 
distribution from NHANES 2011-2012.135 The age standardized prevalence of diabetes was 
10.2% while that of prediabetes was 42.6 (Table 3.3). The age standardized prevalence of 
diabetes in this sample was lower than that of the US but the age standardized prevalence of 
prediabetes was higher (Table 3.3). The age standardized prevalence of the sample was further 





in the sample was lower than that of Non-Hispanic Blacks but the age standardized prevalence of 
prediabetes was still higher.  
 
Discussion 
This study found that the prevalence of diabetes and prediabetes among PLHIV at PHFCC was 
7.0% and 45.5% respectively. Multinomial logistic regression analysis showed that BMI was a 
significant risk factors for prediabetes while age and BMI were significantly associated with 
diabetes. NNRTI usage was associated with a significantly protective effect for diabetes when 
compared with PI based regimens. When the prevalence findings were analyzed among people 
without anemia, older age was associated with higher odds of having diabetes, NNRTI use was 
associated with lower odds of having diabetes and higher BMI was associated with higher odds 
of having prediabetes.  
 
The prevalence of diabetes was concordant with other prevalence studies of diabetes in eastern 
and southern Africa. In addition to Zimbabwe, countries like South Africa, Namibia, DRC and 
Tanzania had comparable national prevalence findings above 6 % for national diabetes 
prevalence.15 It is difficult to compare the prevalence of diabetes among HIV patients at PHFCC 
with the Zimbabwean national prevalence as the current estimates vary significantly. In 2013, the 
6th edition of the IDF Diabetes Atlas reported that Zimbabwe had a prevalence of 8.8% while in 
2015, the IDF 7th edition of the Diabetes Atlas reported a national prevalence of 2.9%.15,91 Given 
these irregularities, it is difficult to compare this finding with the general population. Should the 





HIV positive patients in this sample had a higher prevalence rate of diabetes than the general 
population. 
 
It is similarly difficult to present a comparison of the prediabetes prevalence found in this study 
to that in African countries as there is a paucity of studies that look at the prevalence of diabetes 
and prediabetes among HIV positive patients using HbA1c diagnostic criteria. Existing studies 
that assessed prediabetes prevalence through IGT and/or IFG found lower prevalence rates. 
Moreover, the groups of people identified as having prediabetes and the estimates offered varied 
according to the method/criteria used i.e IFG and/or IGT or HbA1c.94  For example, a study in 
among 35 to 60 year old participants in Eastern Uganda found the prevalence of prediabetes to 
be 8.6% using WHO criteria and 20.2% using ADA HbA1c criteria.99  Some studies in Africa 
have found seemingly high prevalence rates of prediabetes. An Ethiopian study similar to this 
one found a prediabetes prevalence of 22.4% using fasting plasma glucose while a study done in 
Kenya found an IFG prevalence of 20.8%.136-137 It is thus difficult to place the 45.5% percent 
prediabetes in a comparison context with other countries in Africa.  
 
Analysis of the age standardized prevalence of this sample suggests that the PLHIV in our 
sample had a higher prevalence of prediabetes and lower diabetes prevalence (see Table 3.3) 
compared to the US.  The NHANES study that was used to standardize our sample included 
fasting plasma glucose, 2-hour plasma glucose and HbA1c in the definitions of prediabetes.135 
The inclusion of both 2 hour plasma glucose and fasting plasma glucose in our study would have 
increased the prevalence of both prediabetes and diabetes in our sample. This suggests that the 





groups. It also alludes to the possibility of a much higher prevalence of both conditions in our 
sample. 
 
Consistent with the literature, increasing age, PI use and BMI were significantly associated with 
diabetes while BMI was associated with prediabetes.9,138-140 While the literature is still unclear as 
to the precise impact of ART on diabetes, this study found that current use of protease inhibitors 
was associated with higher odds of developing diabetes.  Protease inhibitors and thymidine 
analogs have been associated with diabetes onset through interfering with the glut 4 recruitment, 
lipid metabolism and beta cell function.21, 120 The association between prediabetes and BMI was 
also consistent with other findings.141 
 
The multinomial logistic regression suggests that those with anemia were at an elevated risk for 
prediabetes but not for diabetes. There are various explanations that can help to account for this. 
Different studies have shown that conditions that prolong erythrocyte survival e.g iron 
deficiency, aplastic anemia and some hemoglobinopathies elevate HbA1c leading to possible 
misclassification of prediabetes or diabetes in patients.114, 140, 142  Anemia could also be  
considered an indirect risk factor for diabetes and prediabetes. Anemia is closely associated with 
poverty and malnutrition.143-144 In a social determinants of health perspective, people that are 
likely to live in poverty or are malnourished, are more likely to have a poor diet and this can 
increase the risks of developing diabetes or prediabetes. 143-144 
 
This study was susceptible to additional challenges and limitations. Primary challenges related to 





influenced by a variety of conditions (e.g aplastic anemia, hemoglobinopathies) that affect 
erythrocyte survival.140,142 Other theories portend that ART, induces hemolysis and/or 
macrocytosis which causes HbA1c to underestimate glycemia among patients on ART.106-108 
This would suggest that there is potential for even greater diabetes and prediabetes prevalence 
amongst the study participants as their glycemia may have been underestimated. Furthermore 
there is a growing body of literature which suggests that HbA1c is influenced by race/ethnicity 
and tends to be higher among African Americans.145 Whether or not this race/ethnicity influence 
persists among African patients is still yet to be proven, but could act as an additional influence 
for this study.  
 
Secondary challenges were limitations imposed by the study design. The study had a small 
sample size (n=244). Furthermore, there was occasional missing data in some variables analyzed 
(Table 3.1) and this may have introduced biases into the analysis. The lack of a control group of 
HIV-negative patients prevents comparing the influence of HIV/AIDS and ART on diabetes 
prevalence. Lastly, this study only measured HbA1c as a screening tool for diabetes. In order to 
avoid HbA1c related limitations, a better study design should incorporate another method (e.g a 
75 g Oral Glucose Tolerance) for diabetes diagnosis to better ascertain diabetes status. 
 
This study also offers many strengths. To the knowledge of the researchers, it is one of the 
earliest studies conducted at PHFCC that assess both diabetes and prediabetes prevalence among 
HIV positive patients. It is also one of the few studies that looks at the role of various risk factors 





may be at an elevated risk for developing diabetes. It also highlights that there may be a 
significant proportion of people with diabetes among HIV positive patients at PHFCC.  
 
This study provides a foundation for future studies in Zimbabwe that assess diabetes prevalence 
among PLHIV. Given the aforementioned limitations, future studies ought to target larger 
sample sizes and include control groups from which direct analyses can be conducted.  There is 
need to assess the prevalence of prediabetes among PLHIV. This study found a high prevalence 
of prediabetes and signals the possibility of significant future increases in diabetes among 
PLHIV. Such increases do not only symbolize the growing weight of the double burden of 
disease but call for avant-garde health care structures to be developed that cater to the life-long 


















Additional Analyses and Implications 
 
Even after performing the data analysis presented in chapter 3, further analyses were necessary 
to try account for the observed prevalence of prediabetes and diabetes. This analyses was 
necessitated primarily by the seemingly high prevalence of prediabetes.  The prevalence of both 
diabetes and prediabetes were stratified according to anemia status, recent CD4 status, smoking 
status, alcohol consumption and family history of diabetes.  
 
As previously mentioned in chapter 3, anemia was not considered as a direct risk factor diabetes 
and prediabetes. Given that HbA1c is an unreliable measure of glycemia among people with 
anemia, it was necessary to include anemia in the model as a sensitivity test for the analyses.114 
Table 4.1 shows that after stratifying by anemia status, it was found that people without anemia 
had a similar prevalence of prediabetes (40.8%) to the sample prevalence (45.5%). People with 
anemia had higher prevalence of prediabetes (65.9%).  The prevalence of diabetes was 
comparable between both groups. 
Table 4.1 Prevalence of Outcomes Stratified by Anemia Status 
 No Anemia Anemia Missing P Value 
Normoglycemia 76 (51.7) 11 (26.8) 29 (51.8)  
Prediabetes 60 (40.8) 27 (65.9) 24 (42.8)  
Diabetes 11   (7.5) 3   (7.3) 3 (5.36)  
N    147     41   56 0.0473# 
# P-value calculated using Fisher’s Exact Test 
A further nested analysis was conducted amongst participants (n=147) that did not have anemia 
was conducted and the results are shown Table 4.2 below. The table summarizes the prevalence 





history of diabetes, alcohol consumption, smoking status, drug regimen and CD4 status. In this 
nested analyses, prevalence of diabetes was 7.5% and prediabetes was 40.8%. This was similar 
to the prevalence estimates for the whole group. Age and gender distributions resembled those 
shown in Table 3.1.  
Table 4.2 Distribution of Participant Characteristics by Glycemia Status in Participants Without 
Anemia 







N 147 76 (51.7) 60 (40.8) 11  (7.5)  
Age  (years)~     0.1077 
 18-25 7 4   (5.3) 3    (5.0) 0   (0.0)  
 26-45 64 38 (50.7) 25  (41.7) 1   (9.1)  
 46-65 74 32 (42.7) 32  (53.3) 10 (90.1)  
  >65 1 1    (1.3) 0    (0.0) 0   (0.0)  
Gender~     0.1679 
 Female 94 46 (60.5) 43 (71.7) 5 (45.5)  
Weight Status     0.0011 
Normal weight 72 46 (60.5) 24  (40.0) 2 (18.2)  
 Overweight 45 22 (29.0) 16  (26.7) 7 (63.6)  
 Obesity 30 8 (10.5) 20  (33.3) 2 (18.2)  
Reported History of 
Family Diabetes 
    0.4340 
Yes 35 19 (25.0) 12 (20.0) 7 (63.6)  
No 112 57 (75.0) 48 (80.0) 4 (37.4)  
Smoking     0.4402 
Yes 5 2   (2.6) 2 (3.3) 1   (9.1)  
No 142 74 (97.4) 58 (96.7) 10 (90.9)  
Alcohol consumption     0.1373 
>1 drink per week 8 6   (7.9) 1   (1.7) 1   (9.1)  
1 drink per week 7 2   (2.6) 5   (8.3) 0   (0.0)  
No Alcohol 132 68 (89.5) 54 (90.0) 10 (90.9)  
ART experienced      0.1119 
Currently on PI  19 6 (7.9) 10  (16.7) 3 (27.3)  
 Currently on NNRTI  115 64 (84.2) 45  (75.0) 6 (54.6)  
Not on PI/NNRTI or 
missing 
13 6 (7.9) 5  (8.3) 2 (18.2)  
CD4 count     0.6058 
Above median 70 32 (42.1) 31 (51.7) 7 (63.6)  
Below median 74 42 (55.3) 28 (46.7) 4 (36.4)  
Missing data 3 2   (2.6) 1 (1.7) 0   (0.0)  





A multinomial logistic regression model was then rerun for participants without anemia 
(Table.4.3). In this model, higher BMI (OR 1.11 95% CI 1.04- 1.19) was associated with 
prediabetes but not with diabetes (OR 1.18 95% CI 0.99-1.26). Higher age (OR 1.12 95%CI 
1.04-1.20) was associated with higher odds of diabetes while NNRTI (OR 0.15 95% CI 0.03-
0.09) use was associated with lower odds of having diabetes. 
 
Table 4.3 Results From Multinomial Logistic Regression in Participants Without Anemia 
 Prediabetes Diabetes 
 Odds Ratio 95% CI p-value Odds Ratio 95% CI p-value 
Age (years) 1.01 0.98-1.05 0.5665 1.12 1.04- 1.20 0.0015 
BMI (kg/m2)# 1.11 1.04-1.19 0.0022 1.18 0.99- 1.26 0.0679 
PI Use 1.00 - - 1.00 - - 
    NNRTI Use* 0.45 0.15- 1.38 0.1637 0.15 0.03- 0.90 0.0379 
Missing or Not on 
PI/NNRTI* 
0.59 0.12- 2.99 0.5227 0.71 0.07-7.51 0.7737 
CI, confidence interval; OR, odds ratio. 
*Reference is PI use 
 
In another set of analysis, stratification by CD4 status (Table 4.4) showed similar prevalence of 
diabetes and prediabetes between people with CD4 counts below and above the median. The 
prevalence of prediabetes among people with a CD4 count below the median was 44.0% while 
that among people above the median CD4 count was 46.3%. This finding shows that CD4 count 
was not a principle driver for prediabetes or diabetes prevalence. This finding runs contradictory 
to the claims presented by Kalra et all who maintain that low CD4 account is a viral factor which 









Table 4.4 Prevalence of Outcomes Stratified by CD4 status 




Missing CD4 P Value 
Normoglycemia 56 (51.4) 48 (44.4) 12 (44.4)  
Prediabetes 48 (44.0) 50 (46.3) 13 (48.2)  
Diabetes 5   (4.6) 10 (9.26) 2   (7.4)  
N  109  108     27 0.6479# 
# P-value calculated using Fisher’s Exact Test 
 
Stratification by smoking status (Table 4.5) suggested that those who smoke have a lower 
prevalence of prediabetes (18.2%) compared to non-smokers (46.8%).  The non-significant p-
value (>0.05) indicates, however, that this not the case. It is likely that small sample size of 
smokers affects the enumeration of prevalence results. Smokers only accounted for 4.5% of the 
total participants and because of their low numbers, the apparent low prevalence of prediabetes 
in this group is likely to be caused by sample size. The effect of smoking on diabetes prevalence 
is yet to be fully verified but smoking has been considered a risk factor for increasing diabetes 
prevalence in SSA.146 
 
Table 4.5 Prevalence of Outcomes Stratified by Smoking Status 
 No Smoke Yes Smoke P Value 
Normoglycemia 108 (46.4) 8 (72.7)  
Prediabetes     109 (46.8) 2 (18.2)  
Diabetes   16   (6.9) 1   (9.1)  
N            233              11 0.1227# 
# P-value calculated using Fisher’s Exact Test 
 
Table 4.6 shows no discernable trend among people who do not drink alcohol, who drink one 
drink per week and those that drink more than one per week. The prevalence of prediabetes 





Those that drank one drink per week had a higher albeit comparable prevalence (50.0%) while 
those that drank more than one drink per week had a lower prevalence (21.4%). The small 
samples sizes of those that drink alcohol makes adequate analysis difficult to achieve as those 
that drink one drink per week and those that drank more than one drink per week collectively 
constituted 9.8% of the participants.  
 
Table 4.6 Prevalence of Outcomes Stratified by Alcohol Consumption 
 
Does Not Drink  1 Drink Per Week >1 Drink Per Week 
P 
Value 
Normoglycemia 101 (46.3) 5 (41.7) 10 (71.4)  
Prediabetes 102 (46.8) 6 (50.0) 3 (21.4)  
Diabetes 15   (6.9) 1   (8.3) 1   (7.1)  
N  218      12     14 0.3172# 
# P-value calculated using Fisher’s Exact Test 
Further analysis of the differences in prevalence of diabetes and prediabetes prevalence by 
family history of diabetes also showed similar prevalence of prediabetes (Table 4.7). The 
prevalence of prediabetes in people without a family history of diabetes was 46.2% while that 
among people with a family history of diabetes was 43. 6%. People with a family history of 
diabetes had higher prevalence of diabetes (14.5%) compared to people without a family history 
(4.40). Family history of diabetes is a known risk factor for diabetes and this finding confirms 
this. When family history of diabetes was added to the multinomial logistic model, it was neither 
significantly associated with either diabetes nor with prediabetes. 
Table 4.7 Prevalence of Outcomes Stratified by Family History 
 No Family History Yes Family History P Value 
Normoglycemia 90 ( 49.5) 26 (41.9)  
Prediabetes 84  (46.2) 27 (43.6)  
Diabetes 8    (4.4) 9  (14.5)  
N            182              62 0.0245* 





The above analyses indicate that anemia status, CD4 count status, smoking status, alcohol 
consumption and family history of diabetes did not account for the high prevalence of 
prediabetes. In the tables above, prediabetes prevalence was either comparable or significantly 
higher than the total prediabetes prevalence of 45.5% that was found in the study. This result 
underscores the need for more clinical follow up with patients that have prediabetes. Early 
interventions through healthier diets and exercise can reduce the proportion of people that 
progress to diabetes.  Such timely efforts can have far reaching positive effects such as the 
reduction in mortality and comorbidities that are often associated with diabetes.  
 
This study also trumpets for more monitoring of diabetes among PLHIV. This study included 
only a minor fraction (1.36%) of the clinic’s total population but the results call for additional 
screening for diabetes in order to determine the full extent of the burden of prediabetes and 
prediabetes. From a public health perspective, prevention is always better than a cure. In the 
context of a chronic disease like diabetes, prevention is better than life-long treatment. 
 
 If the trends observed in this study are representative of the prevalence of prediabetes among 
PLHIV, then corresponding changes to the available healthcare infrastructure are necessary. 
Having observed such trends in a review on HIV and Diabetes in Swaziland and Ethiopia, 
Rabkin et al argue for new systems of care that put into consideration the toll that non-
communicable diseases present.134 They state that “access to prevention, care, and treatment 
services for non-communicable diseases like diabetes remains out of reach for most in Sub-





continuity services required to effectively identify patients at risk, engage them in care, and 
retain them for the course of what is usually life-long treatment.”134  
 
In a similar review, Samaras notes that current treatment methods are geared towards “the 
suppression of viral replication and immune system restoration. However the cardiometabolic 
sequalea of HIV treatment, in addition to the aging of the HIV-infected populations have 
extended the complexity of care to management of comorbidities such as diabetes and 
cardiovascular disease.”133 From this view, it is no longer enough for HIV care to attempt to 
control and suppress HIV, a complete provision of care must ultimately begin to address the 
unintended ailments that have sprung up from the advent of HIV suppression and the rise of non-
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